Presentation on theme: "EU support for Health Research: from FP6 to FP7"— Presentation transcript:
1 EU support for Health Research: from FP6 to FP7 Beatrice LucaroniUnit F4DG Research - European CommissionFerrara – 25 Ottobre 2006
2 EU Health Research Perspectives for the 7th Framework Programme The details of the FP7 priorities and modalities are still in negotiation and subject to change. In particular the EC’s proposal for the Joint Technology Initiative for Innovative Medicines will be subjected to the approval of the European Council.
3 Role of EC in researchEuropean Commission programmes bring down barriersbetween countries:multinational consortia in Europe (EU-25 + associated countries)researchers from almost any country in the world can participate;and promotes coordination of national funding programmes (ERA)between different types of organizations: universities, research centres, SMEs, large companies, etc.between disciplines: focus on translational researchand encourages mobility: Marie Curie fellowships for researchers and for host institutes, including ingoing & outgoing grants.
4 EC Research Framework Programme 6 (2003-2006) €2.4 billion in research grants for 604 projects in 4 yearsAverage success rate for projects: 25.4%Total number of participants: 7,426Project typenumberav. EU contributionpartnersIntegrated Projects119€ 10.0m21Networks of Excellence40€ 9.3m30STREPs322€ 2.2m8Coordination Actions25€ 1.1m19Specific Support Actions98€ 0.4m6
5 Special call for SME projects in Health research (2006) 355 proposals received: 86 projects funded€ 200 million granted: 43% going to SMEsAverage budget requested per SME: € 342,000~270 SMEs involved (41% of participants)40/86 projects (46%) coordinated by SMEsObservations:SMEs taking leading role in projectsprojects aligned with SME’s strategySME gaining experience in EC funding schemes
6 FP7: main elementsBudget to be increased: €50.5 billion over 7 years %European Research Council ( Ideas )Collaborative research ( Cooperation )continuity in themes & instruments.funding levels to be raised in some cases, eg SMEs: 50% 75%Joint Technology InitiativesInfrastructures, SMEs, regions & potential ( Research Capacities )Human potential and science careers ( People )Reminder:The European Commission currently manages about 5% of total public spending in R&D in the European Union.The EU currently invests about 1.9% of GDP in research
8 Cooperation: Collaborative research in FP7 Thematic PrioritiesHealthFood, agriculture and biotechnologyInformation and communication technologiesNanosciences, nanotechnologies, materials and new production technologiesEnergyEnvironment (including climate change)Transport (including aeronautics)Socio-economic sciences and the humanitiesSecurity and space+ Euratom: fusion energy research, nuclear fission and radiation protection
9 Collaborative research for Health in FP7 Main policy drivers:Improving health of European citizensIncreasing competitiveness of European health-related industries and businessesAddressing global health issues, including emerging epidemics
10 Collaborative research for Health in FP7 Budget:€6 billion over 7 years ( )Activities in 3 main areasBiotechnology, generic tools and technologies for human healthTranslating research for human healthOptimising the delivery of healthcare
11 Collaborative research for Health in FP7 1: Biotechnology, generic tools and technologiesHigh-throughput research enhancing data generation, standardisation, acquisition & analysisDetection, diagnosis and monitoring with emphasis on non-invasive or minimally invasive approachesInnovative therapeutic approaches and interventions gene and cell therapy, regenerative medicine, transplantation, immunotherapy and vaccines, implants & prostheticsPredicting suitability, safety and efficacy of therapies develop and validate parameters, tools, methods and standards (mainly through IMI) and alternatives to animal testing
12 Collaborative research for Health in FP7 2: Translating research for human healthIntegrating biological data and processes: large-scale data gathering, systems biologyResearch on the brain and related diseases, human development and ageingTranslational research in major infectious diseases: to confront major threats to public health antimicrobial drug resistance, HIV/AIDS, malaria and TB, emerging epidemics, neglected infectious diseasesTranslational research in other major diseases: cancer, cardiovascular disease, diabetes and obesity, rare diseases, and other chronic diseases
13 Collaborative research for Health in FP7 3: Optimising the delivery of health careEnhanced health promotion and disease prevention (providing evidence of best public health measures – life styles, interventions, special focus on mental health, etc.)Translating clinical research into clinical practice (patient safety, better use of medicines, benchmarking, pharmacovigilance, etc.)Quality, solidarity and sustainability of health systems (organisational and financial aspects, health systems, etc.)
14 Collaborative research for Health in FP7 Two other issues will be addressed across all activities:Child healthThe health of the ageing populationFor more information see Specific programme:
15 Collaborative research for Health in FP7 Special encouragement and measures for:SMEsParticipation of SMEs and larger companies in all areasSpecial topics for SMEsInternational CooperationParticipation possible in all areasSpecial International Cooperation Actions (SICA)
16 Translational sciences Dialog among basic and clinical scientists Clinical researchForward Translation:Use bioinformatics, functional genomics into clinical practiceDevelop biomarkers & molecular imaging techniques at early stage of target validationPhase I – II – IIIstudiesIn vitro studiesAnimal modelsReverse Translation:Validating the biochemistry in target & biomarker discoveryBring measurements from the clinic into earlier stages of basic researchTarget validationBasic research
17 Collaborative research for Health in FP7 SUMMARYContinuity in collaborative Health research to:develop new tools and technologiespromote translational researchenhanced efforts to optimise delivery of health care[ using usual FP funding and coordination mechanisms ]&A novel approach to improve drug development:The Innovative Medicines Initiative[ using the proposed Joint Technology Initiative in FP7 ]
18 Research funding schemes in FP7 Funding instruments proposed:Collaborative projects to develop new knowledge, new technology, products, demonstration activitiesSmall or medium-sized focused research actionsLarge-scale integrating projectsProjects targeted at special groups (eg SMEs or International)Networks of ExcellenceCoordination and support actionsSupport for investigator driven research by individual teams (ERC)Support for training and career development of researchersResearch for the benefit of specific groups (in particular SMEs)
19 Basic principles of evaluation and funding Annual calls for proposals, with topics set by the EC (following consultation and approval by Member States).Proposals evaluated by panels of independent experts (being an expert for the EC is a valuable experience)Criteria and thresholdsProposals short-listed for funding (with recommendations)Consortia receive EC funding for R&D tasks (shared cost) and for project management12- of 18-month reports and reviews
20 Collaborative research for Health in FP7 Next steps:Approval by Council and European ParliamentPreparation of work programmes for years 1 & 2.Currently consulting Member and Associated States (PC)First calls for proposals: Dec (tbc)first deadline end-March ’07 (tbc)second deadline end-June ’07 (tbc)[ not all areas will be open at in each call ]
21 Information on FP7 EU research: http://europa.eu.int/comm/research Seventh Framework Programme:Information on research programmes and projects:RTD info magazine:Innovative Medicines InitiativeInformation requests:
Your consent to our cookies if you continue to use this website.